In a clinical trial (Trial registration ID: NCT02111863) among 6 patients with melanoma who underwent adoptive transfer with CD137-selected TILs, only 1 patient achieved partial response, and the remaining 5 progressed. The gene discussed is TNFRSF9; the disease is melanoma.